Opens in a new tab

Dr. Shen Jingnan

Chinese name: 沈靖南
Professor, Chief Physician, Doctoral Supervisor . Orthopaedic Oncology (Bone Tumours)
Professor Shen Jingnan is academic leader of the Bone Tumour Department at the First Affiliated Hospital of Sun Yat-sen University and a professor of orthopaedic surgery. He specialises in the diagnosis and limb-salvage treatment of malignant bone and soft-tissue tumours, including complex pelvic and spinal tumour resection and reconstruction, and is a Zhongshan leading physician.

Private & confidential

No obligation

Coordinated end-to-end by Orisene

35+ years
Orthopaedic oncology clinical practice
59
SCI-indexed publications as first or corresponding author
22
National and provincial research projects led

  • The Physician

About Dr. Shen Jingnan

Professor Shen Jingnan is academic leader of the Bone Tumour Department at the First Affiliated Hospital of Sun Yat-sen University and a professor of orthopaedic surgery. He has devoted more than thirty years to bone and soft-tissue tumours, with expertise in preoperative needle biopsy diagnosis, limb-salvage surgery for malignant bone tumours, and the resection and reconstruction of pelvic and spinal tumours. He also uses chemotherapy, targeted therapy and immunotherapy to treat malignant bone tumours and is particularly experienced in limb-salvage surgery for children, helping young patients keep their limbs and function.
1、Academic leader of the Bone Tumour Department at the First Affiliated Hospital of Sun Yat-sen University
2、Professor and doctoral supervisor of orthopaedic surgery
3、One of Sun Yat-sen University’s first famous doctors and a Yangcheng Good Doctor
4、Expert in limb-salvage surgery and reconstruction for malignant bone tumours
5、Author of studies on limb-salvage surgery and outcomes in osteosarcoma
6、Leader in developing paediatric bone tumour surgery and prosthetic reconstruction

Dr. Shen Jingnan ’s Three Key Areas of Expertise

Three areas of focused expertise, each supported by a deep subspecialty team, high case volumes and an English-speaking care pathway coordinated by Orisene.

Malignant bone tumours

He diagnoses and treats osteosarcoma, Ewing sarcoma and other malignant bone tumours with limb-salvage surgery, chemotherapy and targeted therapy, planning resection to remove the tumour completely while preserving the limb and its function for patients of all ages in clinical practice.

Limb-salvage surgery in children

He performs limb-salvage surgery and reconstructive procedures in children with bone tumours, using customised prostheses, vascularised bone grafts and lengthening techniques to remove the tumour while preserving limb length, growth and function for young patients as they grow and develop into adulthood.

Pelvic and spinal tumour resection

He performs complex resection and reconstruction of pelvic and spinal tumours, and soft-tissue sarcoma surgery, combining surgical skill with chemotherapy and immunotherapy to control disease and preserve function in patients with difficult, high-risk tumours and extensive disease in routine clinical practice.

More：soft-tissue sarcoma——surgery; bone metastasis——treatment; biopsy diagnosis——needle biopsy; prosthetic reconstruction——limb salvage; paediatric bone tumour——management

  • Clinical Practice & Publications

Selected cases, research & publications

Representative work drawn from documented clinical treatments, publicly indexed literature, and hospital project records, reflecting the depth of this physician's hands-on expertise and academic rigor.
1. Chromosomal Translocation-Derived Rab22a Fusion Proteins Drive Osteosarcoma Lung Metastasis
This landmark study identified RAB22A exon-intron fusion genes in osteosarcoma that produce Rab22a-NeoF fusion proteins. These proteins release GTP-bound RhoA via SmgGDS-607 and promote pulmonary metastasis. A synthetic blocking peptide prevented lung metastasis in orthotopic models, revealing a promising therapeutic target for osteosarcoma patients with lung metastasis.
2. Targeting Super-Enhancer-Associated Oncogenes with the CDK7 Inhibitor THZ2
This study showed that super-enhancer-associated oncogenes drive osteosarcoma malignancy. The covalent CDK7 inhibitor THZ2 selectively suppressed these oncogenic transcriptional programs, inhibiting tumour growth and metastasis in vitro and in vivo. Targeting super-enhancer-driven transcription with THZ2 represents a promising therapeutic strategy for patients with osteosarcoma, especially those with aggressive or chemoresistant disease.
3. Telangiectatic Osteosarcoma: Outcomes and a Diagnostic Model to Distinguish It from Aneurysmal Bone Cyst
Reviewing 51 telangiectatic osteosarcoma patients treated at the First Affiliated Hospital of Sun Yat-Sen University, this study defined diagnostic and prognostic factors distinguishing this rare subtype from aneurysmal bone cyst. A Bayes discriminant model using age, pathological fracture and blood markers improved diagnostic accuracy. Smaller tumours and normal LDH predicted better survival, guiding clinical management.
4. MCT1 Downregulation Suppresses Osteosarcoma Growth and Metastasis via NF-kB
This study demonstrated that monocarboxylate transporter 1 (MCT1) is overexpressed in osteosarcoma and supports tumour growth and metastasis. Downregulating MCT1 inhibited proliferation, invasion and metastasis through suppression of the NF-kB signalling pathway. The findings highlight MCT1 as a potential molecular target and prognostic marker, offering a rationale for targeted therapy in osteosarcoma patients with aggressive disease.
5. Cordycepin Enhances Osteosarcoma Chemosensitivity to Cisplatin via AMPK Activation
This study showed that cordycepin, a natural nucleoside analogue, inhibits osteosarcoma proliferation and invasion and induces apoptosis by activating AMPK and suppressing AKT/mTOR signalling. Combining cordycepin with cisplatin markedly enhanced chemosensitivity in vitro and in vivo. The results suggest cordycepin as a promising agent to overcome chemotherapy resistance and improve outcomes for osteosarcoma patients.
6. Long Non-Coding RNA DANCR Promotes Osteosarcoma Progression and Cancer Stemness
This study revealed that the long non-coding RNA DANCR is elevated in osteosarcoma tissues and promotes proliferation, invasion and stemness. DANCR upregulates the receptor tyrosine kinase AXL by competitively binding miR-33a-5p, activating PI3K-AKT signalling. High DANCR expression correlates with tumour size and metastasis and independently predicts poor prognosis, suggesting a valuable biomarker and therapeutic target.
  • Affiliated Hospital

Where Dr. Shen Jingnan practices

Guangzhou

The First Affiliated Hospital, Sun Yat-sen University

Chinese name: 中山大学附属第一医院
Founded in 1910, the First Affiliated Hospital of Sun Yat-sen University, a national comprehensive medical university hospital, holds 36 national clinical key specialties, serves 15,000 daily outpatients, achieved A++ national performance rating and pioneered the world's first ischemia-free organ transplant.
Since 1910
116 years of care
36
National key specialties
15,000+
Daily outpatient visits
327
National key specialties
View Hospital Profile
Appointments with this physician are booked through official hospital channels only, coordinated end-to-end by Orisene.
  • WHY INTERNATIONAL PATIENTS CHOOSE CHINA

Why patients travel to China for treatment

Six reasons international patients now put China on their shortlist — from internationally aligned clinical capability to the policy channels that make treatment here genuinely reachable.

Clinical capability at international standard

Chinese hospitals deliver internationally aligned protocols, performing vast volumes of advanced robotic, minimally invasive, and complex transplant surgeries annually. This massive clinical data and highly specialized workforce ensure world-class outcomes, even for rare and complex cases.

Diagnostics and treatment in days, not months

A full medical workup that typically means months of waiting elsewhere is completed in China within 48–72 hours. Imaging, labs, and multidisciplinary consultations are integrated into a single visit, allowing treatment to commence immediately.

Transparent, itemised pricing

Chinese healthcare offers legally binding, itemised cost estimates before treatment begins, eliminating hidden fees or surprise billing. Due to national centralized procurement, total expenses remain 40–70% lower than comparable care in Western Europe or North America.

Policy channels that open the door

China facilitates access through 240-hour visa-free transit and dedicated medical visa routes. Policies like the Greater Bay Area drug pathway and Boao Lecheng’s pilot zone allow designated hospitals to administer innovative therapies not yet globally approved.
  • International Patient Guide

Consulting this physician, step by step

From the first message to the follow-up after you fly home, one coordinator, no paperwork on your side.
01
Day 0
  • Share your story
    A private consultation with an Orisene advisor, by message, phone or video. Send medical records in any language. Nothing is shared with the hospital yet.
02
Days 1–3
  • Records review & matching
    Orisene translates and presents your case to the right specialist. The hospital returns a tailored care plan, with costs itemised once that plan is confirmed.
03
Days 3–7
  • Your consultation
    Appointments are booked through official hospital channels only. Your navigator accompanies every visit with real-time interpretation, so you can focus on one thing: being cared for.
04
After you fly home
  • Reports & follow-up
    Translated reports and prescriptions delivered within days, remote follow-up coordination with your physicians at home, and a standing line to your navigator.
Orisene offers English and multilingual services, a professional medical interpreter at every consultation, plus translation of your records, reports and prescriptions.

Ready to plan your consultation with Dr. Shen Jingnan?

Send your records in any language. An Orisene advisor will reply within 2 hours, present your case to the right specialist, and return a tailored care plan with itemised costs, before anything is booked. Simple. Private. Efficient.
Contact

Confidential, permanently

Independent — no hospital commission

We never handle medical fees

Information Sources

This physician profile is compiled by the Orisene team from publicly available online sources and verified at the time of publication. Details may change, and physician availability is confirmed at the time of booking.

Disclaimer: This information is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal medical guidance.

Mention of any specific product, brand, or manufacturer is for informational purposes only and does not constitute an endorsement or recommendation by Dr. Shen Jingnan.